中文别名 |
AZD6244中间体;Daclatasvir 达卡他韦;Daclatasvir标准品;N,N''-[[1,1''-联苯]-4,4''-二基双[1H-咪唑-5,2-二基-(2S)-2,1-吡咯;N,N-[[1,1-联苯]-4,4-二基双[1H-咪唑-5,2-二基-(2S)-2,1-吡咯;N,N'-[[1,1'-联苯]-4,4'-二基双[1H-咪唑-5,2-二基-(2S)-2,1-吡咯烷二基 [(1S)-1-(1-甲基乙基)-2-氧代-2,1-乙烷二基]]]双氨基甲酸 C,C'-二甲酯;达卡他韦;达卡他韦靶向药;达卡他韦中间体;德他韦尔;达卡他韦(Daclatasvir,BMS-790052);达卡他伟;达卡拉韦盐酸盐;达卡他韦(API);达卡他韦, 高度选择性的HCV NS5A抑制剂;DACLATASVIR (BMS-790052) N,N'-[[1,1'-联苯]-4,4'-二基双[1H-咪唑-5,2-二基-(2S)-2,1-吡咯烷二基 [(1S)-1-(1-甲基乙基)-2-氧代-2,1-乙烷二基]]]双氨基甲酸 C,C'-二甲酯;达拉他韦 |
英文别名 |
Dimethyl (2S, 2'S)-1, 1'-((2S, 2'S)-2, 2'-(4, 4'-(biphenyl-4, 4'-diyl)bis(1H-imidazole-4, 2-diyl))bis(pyrrolidine-2, 1-diyl))bis(3-methyl-1-oxobutane-2, 1-diyl)dicarbamate (Related Reference);Daclatasvir (BMS-790052);BMS790052;BMS-790052;BMS-790052(Daclatasvir);Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl este;Daclatasvir;Daclatasvir-D16;Daclatasvir-D6;Daclatavir;Dimethyl (2S, 2'S)-1, 1'-((2S, 2'S)-2, 2'-(4, 4'-(biphenyl-4, 4'-diyl)bis(1H-imidazole-4, 2-di...;Dimethyl (2S, 2'S)-1, 1'-((2S, 2'S)-2, 2'-(4, 4'-(biphenyl-4, 4'-diyl)bis(1H-imidazole-4, 2-diyl))bis(pyrrolidine-2, 1-diyl));dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1Himidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate;Carbamic acid, N,?N'-?[[1,?1'-?biphenyl]?-?4,?4'-?diylbis[1H-?imidazole-?5,?2-?diyl-?(2S)?-?2,?1-?pyrrolidinediyl[(1S)?-?1-?(1-?methylethyl)?-?2-?oxo-?2,?1-?ethanediyl]?]?]?bis-?, C,?C'-?dimethyl ester;EBP 883;N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester;Daklinza;Dacaltasvir;Dhaka He Wei;methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate;1009119-64-5;AC-28958;Methyl [(2S)-1-{(2S)-2-[5-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}biphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate;HY-10466;BRD-K82861010-001-02-5;Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester; BMS 790052; Daclatasvir; Daklinza; EBP 883;Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester;BDBM50387084;BDBM627982;NCGC00346533-09;SW219754-1;SCHEMBL17897804;EN300-27736661;CCG-270425;s1482;methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate;DIMETHYL N,N'-((1,1'-BIPHENYL)-4,4'-DIYLBIS(1H-IMIDAZOLE-5,2-DIYL-((2S)-PYRROLIDINE-2,1-DIYL)((1S)-3-METHYL-1-OXOBUTANE-1,2-DIYL)))DICARBAMATE;methyl-N-[(2s)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl] pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1himidazol-2-yl]pyrrolidin-1-yl]3-methyl-1-oxobutan-2-yl]carbamate;EBP-883;D10065;NS00072904;SCHEMBL2756027;DB09102;Q5207712;DACLATASVIR ... |